Furosemide (Frusemide) A Pharmacokinetic/Pharmacodynamic Review (Part I)

@article{BolesPonto1990FurosemideA,
  title={Furosemide (Frusemide) A Pharmacokinetic/Pharmacodynamic Review (Part I)},
  author={Laura L Boles Ponto and Ronald D. Schoenwald},
  journal={Clinical Pharmacokinetics},
  year={1990},
  volume={18},
  pages={381-408}
}
SummaryFurosemide (frusemide) is a potent loop diuretic used in the treatment of oedematous states associated with cardiac, renal and hepatic failure, and for the treatment of hypertension. Therapy is frequently complicated by apparently erratic systemic availability from the oral route and from unpredictable responses to a given dosage. The exact mechanism of action is not fully understood, but furosemide is believed to act at the luminal surface of the ascending limb of the loop of Henle by… Expand
Pharmacokinetics and pharmacodynamics of azosemide
TLDR
The diuretic effects of azosemide were dependent on the rate and composition of fluid replacement in rabbits; therefore, this factor should be considered in the evaluation of bioequivalence assessment. Expand
Clinical Pharmacokinetics and Pharmacodynamics of Torasemide
TLDR
The new loop diuretic torasemide belongs to the pyridine sulfonylurea class and yields a bioavailablity of about 80% in healthy individuals, even higher in patients with oedema, and its pharmacokinetics are significantly influenced by liver disease. Expand
Absorption of High Dose Furosemide (Frusemide) in Congestive Heart Failure
TLDR
It is concluded that the presence of massive oedema in patients with congestive heart failure has a minor influence on the pharmacokinetics and pharmacodynamics of high dose oral furosemide. Expand
Pharmacokinetic Changes in Patients With Oedema
TLDR
Besides affecting absorption and conversion of the prodrug to the active form, probably as a result of the associated disease, oedema has not been proven to cause any clinically relevant changes in pharmacokinetic parameters for individual drugs. Expand
Furosemide Pharmacokinetics and Pharmacodynamics following Gastroretentive Dosage Form Administration to Healthy Volunteers
TLDR
The unfolding controlled‐release GRDF of furosemide improved the pharmacodynamic actions due to the sustained absorption in the stomach and jejunum, which delayed the body's counteractivity to the drug effect. Expand
Pharmacokinetics of Furosemide in Patients with Chronic Renal Failure
TLDR
The pharmacokinetics of furosemide (frusemide) were studied after single intravenous and oral doses in 10 patients with chronic renal insufficiency in a randomised, crossover trial since it was comparable with data found in healthy subjects. Expand
Clinical Pharmacology of the Loop Diuretics Furosemide and Bumetanide in Neonates and Infants
TLDR
Comparison of continuous infusion versus intermittent infusion of furosemide showed that the diuresis is more controlled with fewer hemodynamic and electrolytic variations during continuous infusion, and the risk of failure of patent ductus arteriosus closure when indomethacin or ibuprofen have been co-administered is reduced. Expand
Furosemide as a functional marker of acute kidney injury in ICU patients: a new role for an old drug
TLDR
Recent reports and metanalysis suggest that the diuretic response under continuous infusion may allow assessing glomerular and tubular functions with increased reliability than a bolus dose, however, validation studies are still needed to support continuous infusion as a stress test. Expand
Population pharmacokinetic modeling of furosemide in patients with hypertension and fluid overload conditions.
TLDR
The final population pharmacokinetics model was demonstrated to be appropriate and effective and it can be used to assess the pharmacokinetic parameters of furosemide in Indian patients with hypertension and fluid overload conditions. Expand
Pharmacokinetics and pharmacodynamics of furosemide in protein-calorie malnutrition
TLDR
The influence of dietary protein deficiency on pharmacokinetics and pharmacodynamics of furosemide was investigated after iv bolus and oral administration to male Sprague-Dawley rats fed on a 23% or a 5% protein diet ad lib for 4 weeks. Expand
...
1
2
3
4
5
...